Literature DB >> 15202777

Differential interactions of desipramine with amphetamine and methamphetamine: evidence that amphetamine releases dopamine from noradrenergic neurons in the medial prefrontal cortex.

James R Shoblock1, Isabelle M Maisonneuve, Stanley D Glick.   

Abstract

Amphetamine is more effective than methamphetamine at raising dopamine levels in the prefrontal cortex. The current study tested the hypothesis that norepinephrine transporters are involved in this difference. Using microdialysis, dopamine, norepinephrine, and serotonin were measured in the rat prefrontal cortex after administration of methamphetamine or amphetamine, with and without perfusion of desipramine. Amphetamine raised norepinephrine levels more than methamphetamine did. Desipramine raised dopamine and serotonin levels but did not alter metabolite levels. Desipramine attenuated the increase in dopamine by amphetamine while increasing the dopamine released by methamphetamine. These data suggest that methamphetamine and amphetamine differ in altering prefrontal cortical dopamine levels and in interacting with norepinephrine transporters. It is proposed that amphetamine releases dopamine in the prefrontal cortex primarily through norepinephrine transporters, whereas methamphetamine interacts minimally with norepinephrine transporters.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15202777     DOI: 10.1023/b:nere.0000026409.76261.f3

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  26 in total

1.  Medial prefrontal cortical output neurons to the ventral tegmental area (VTA) and their responses to burst-patterned stimulation of the VTA: neuroanatomical and in vivo electrophysiological analyses.

Authors:  S M Au-Young; H Shen; C R Yang
Journal:  Synapse       Date:  1999-12-15       Impact factor: 2.562

2.  Effects of catecholamine uptake blockers in the caudate-putamen and subregions of the medial prefrontal cortex of the rat.

Authors:  M S Mazei; C P Pluto; B Kirkbride; E A Pehek
Journal:  Brain Res       Date:  2002-05-17       Impact factor: 3.252

3.  Blockade of the noradrenaline carrier increases extracellular dopamine concentrations in the prefrontal cortex: evidence that dopamine is taken up in vivo by noradrenergic terminals.

Authors:  E Carboni; G L Tanda; R Frau; G Di Chiara
Journal:  J Neurochem       Date:  1990-09       Impact factor: 5.372

4.  d-Amphetamine as a releaser or reuptake inhibitor of biogenic amines in synaptosomes.

Authors:  M Raiteri; A Bertollini; F Angelini; G Levi
Journal:  Eur J Pharmacol       Date:  1975-11       Impact factor: 4.432

5.  Dopamine uptake through the norepinephrine transporter in brain regions with low levels of the dopamine transporter: evidence from knock-out mouse lines.

Authors:  Jose A Morón; Alicia Brockington; Roy A Wise; Beatriz A Rocha; Bruce T Hope
Journal:  J Neurosci       Date:  2002-01-15       Impact factor: 6.167

6.  The antipsychotic drug risperidone interacts with auto- and hetero-receptors regulating serotonin output in the rat frontal cortex.

Authors:  P Hertel; G G Nomikos; T H Svensson
Journal:  Neuropharmacology       Date:  1999-08       Impact factor: 5.250

7.  Dopamine axon varicosities in the prelimbic division of the rat prefrontal cortex exhibit sparse immunoreactivity for the dopamine transporter.

Authors:  S R Sesack; V A Hawrylak; C Matus; M A Guido; A I Levey
Journal:  J Neurosci       Date:  1998-04-01       Impact factor: 6.167

8.  Cocaine-sensitive and -insensitive dopamine uptake in prefrontal cortex, nucleus accumbens and striatum.

Authors:  J D Elsworth; J R Taylor; P Berger; R H Roth
Journal:  Neurochem Int       Date:  1993-07       Impact factor: 3.921

9.  Effect of 3,4-methylenedioxymethamphetamine (MDMA) on hippocampal dopamine and serotonin.

Authors:  M Shankaran; G A Gudelsky
Journal:  Pharmacol Biochem Behav       Date:  1998-12       Impact factor: 3.533

10.  Effects of reserpine on extracellular caudate dopamine and hippocampus norepinephrine responses to amphetamine and cocaine: mechanistic and behavioral considerations.

Authors:  S M Florin; R Kuczenski; D S Segal
Journal:  J Pharmacol Exp Ther       Date:  1995-07       Impact factor: 4.030

View more
  10 in total

1.  Frontal and temporal dopamine release during working memory and attention tasks in healthy humans: a positron emission tomography study using the high-affinity dopamine D2 receptor ligand [11C]FLB 457.

Authors:  Sargo Aalto; Anna Brück; Matti Laine; Kjell Någren; Juha O Rinne
Journal:  J Neurosci       Date:  2005-03-09       Impact factor: 6.167

2.  The effects of d-amphetamine on extrastriatal dopamine D2/D3 receptors: a randomized, double-blind, placebo-controlled PET study with [11C]FLB 457 in healthy subjects.

Authors:  Sargo Aalto; Jussi Hirvonen; Valtteri Kaasinen; Nora Hagelberg; Jaana Kajander; Kjell Någren; Timo Seppälä; Juha O Rinne; Harry Scheinin; Jarmo Hietala
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-11-05       Impact factor: 9.236

3.  The Addition of Amphetamine to Potentially Sedating Medication Regimens: An Exploratory Investigation of the Impact upon Reaction Time and Sustained Attention.

Authors:  James W Price
Journal:  Psychopharmacol Bull       Date:  2017-05-15

4.  Cortical glutamate-dopamine interaction and ketamine-induced psychotic symptoms in man.

Authors:  Sargo Aalto; Jouni Ihalainen; Jussi Hirvonen; Jaana Kajander; Harry Scheinin; Heikki Tanila; Kjell Någren; Harry Vilkman; Lars L Gustafsson; Erkka Syvälahti; Jarmo Hietala
Journal:  Psychopharmacology (Berl)       Date:  2005-10-19       Impact factor: 4.530

Review 5.  New Drugs to Treat ADHD: Opportunities and Challenges in Research and Development.

Authors:  David J Heal; Jane Gosden; Sharon L Smith
Journal:  Curr Top Behav Neurosci       Date:  2022

6.  A new strategy for antidepressant prescription.

Authors:  Francis Lavergne; Thérèse M Jay
Journal:  Front Neurosci       Date:  2010-11-19       Impact factor: 4.677

7.  Environmental enrichment reduces methamphetamine cue-induced reinstatement but does not alter methamphetamine reward or VMAT2 function.

Authors:  Rebecca S Hofford; Mahesh Darna; Carrie E Wilmouth; Linda P Dwoskin; Michael T Bardo
Journal:  Behav Brain Res       Date:  2014-05-10       Impact factor: 3.332

8.  C57BL/6J mice show greater amphetamine-induced locomotor activation and dopamine efflux in the striatum than 129S2/SvHsd mice.

Authors:  Rong Chen; Minjia Zhang; Soo Park; Margaret E Gnegy
Journal:  Pharmacol Biochem Behav       Date:  2007-05-04       Impact factor: 3.533

9.  Dysfunctional GABAergic inhibition in the prefrontal cortex leading to "psychotic" hyperactivation.

Authors:  Shoji Tanaka
Journal:  BMC Neurosci       Date:  2008-04-25       Impact factor: 3.288

Review 10.  Amphetamine, past and present--a pharmacological and clinical perspective.

Authors:  David J Heal; Sharon L Smith; Jane Gosden; David J Nutt
Journal:  J Psychopharmacol       Date:  2013-03-28       Impact factor: 4.153

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.